AI Article Synopsis
- The study aimed to evaluate the effectiveness of Shexiang Baoxin Pill (SBP) in patients with carotid atherosclerosis (CAS).
- Forty-one patients were split into two groups: one receiving SBP with regular treatment and the other just regular treatment for 6 months.
- Results showed significant improvements in the SBP group, with reductions in plaque size, inflammatory markers, and no serious side effects reported.
Article Abstract
Objective: To study the effects of Shexiang Baoxin Pill (SBP) in treating carotid atherosclerosis (CAS).
Methods: Forty-one CAS patients were randomly assigned to 2 groups, the SBP group (31 cases) treated with SBP plus routine treatment and the control group (10 cases) with routine treatment only. Both were treated for 6 months. The changes of carotid atheromatous plaque (CAP), C reactive protein (CRP), fibrinogen (FIB), D-dimer and blood lipids, etc. were observed.
Results: After treatment, average number, total scores and area of plaque, as well as levels of CRP, FIB and D-dimer decreased significantly in the SBP group (P < 0.05 or P < 0.01), and were lower than those in the control group after treatment respectively (P < 0.05). No severe adverse reaction occurred in both groups.
Conclusion: SBP is a safe and effective remedy for treatment of CAS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!